ClinicalTrials.gg
CompletedNCT04855292Updated Jun 22, 2023

A Study of TG103 Injection in Overweight/Obese Subjects Without Diabetes

A Phase 1 interventional study of TG103 injection and Placebo in Diabetes, sponsored by CSPC Baike (Shandong) Biopharmaceutical Co., Ltd.. Completed at 1 site in China. Open to participants aged 18 Years to 75 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2023-06-22.

Sponsored by CSPC Baike (Shandong) Biopharmaceutical Co., Ltd. (part of CSPC Pharmaceutical Group Limited) · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
48
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 417 studies in Diabetes Mellitus with a site in China — 100 open to participants now, 117 under way, 11 of them phase 3. Diabetes Mellitus · China.

Enrollment
205th of 280
48 · median 143
Started
2021
with 20 others
Phase 1
49 of 417
8 open now
Registered
228th of 417
by date

Among the 417 studies in Diabetes Mellitus with a site in China, this one is the 205th largest by enrollment of the 280 interventional ones that give a count, is one of 21 that started in 2021, is one of 49 in phase 1, and was the 228th registered.

Diabetes Mellitus

8,293 studies on the registry are indexed under Diabetes Mellitus; 1,072 are open to participants now.

Browse Diabetes Mellitus studies →

Open to participants now

100 of the 417 studies in Diabetes Mellitus with a site in China are open now. Recruiting first, the newest first:

95 more — sign in →

All 100 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 648 Diabetes Mellitus studies recruiting now, 357 (55%) set no upper age limit and 195 (30%) stop at 75 or younger; 88 take children under 18; 182 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 417 studies in Diabetes Mellitus with a site in China, or all of them as a file.
02

Study summary

The main purpose of this study is to assess the safety and tolerability of multiple doses of TG103 injection in overweight/obese subjects without diabetes

Read the detailed description

This study is a randomized, double-blind, placebo-controlled, multiple-doses, parallel-group study to characterize the safety (including the anti-drug antibodies (ADA)), tolerability, pharmacokinetics (PK) and pharmacodynamics (PD) of TG103 injection. The study will consist of 3 periods: an approximately 4-week screening period, followed by a 12-week treatment period, and a 3-week safety follow-up period. Eligible subjects will be enrolled into three paralleled dose groups (15 mg, 22.5 mg and 30 mg) with 16 subjects in each group. Within each group, subjects will be randomized in a 3:1 ratio to receive TG103 injection or placebo subcutaneously (SC) once a week (QW) over a period of 12 weeks. Each group will be started at a low dose of 7.5 mg and gradually up-titrated at weekly intervals until the target dose.

03

Conditions studied

  • Diabetes

Browse trials for

04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Age between 18 and 75 years (inclusive); no gender limitation;
  2. (BMI) ≥ 26.0 kg/m2, BMI = weight(kg)/height2 (m2); body weight ≥ 60 kg; Stable body weight (less than 5% self-reported change within 3 months);
  3. Fasting blood glucose 3.9-7.0 mmol/L (exclusive) and the \< 6.5%;
  4. Subjects of childbearing age must use reliable methods of from the date of signing an to at least 6 months after the last dose;
  5. Subjects who fully understand the study, voluntarily participate in the trial and sign the informed consent form。

Exclusion criteria

Exclusion Criteria:

  1. History of allergy to Glucagon-like peptide-1 (GLP-1) analogues, or history of serious allergy to drugs or food;
  2. Secondary obesity, such as obesity induced by metabolic disease (e.g., Cushing's syndrome, hypothyroidism etc.) or drug treatment (e.g. with , tricyclic anti-depressants, atypical anti-psychotics);
  3. Subjects have confirmed diagnosis of type 1 or type 2 diabetes;
  4. History of or current pancreatitis (history of chronic or acute pancreatitis);
  5. Previous abnormal gastric emptying (e.g., gastric outlet obstruction) and severe chronic gastrointestinal diseases (e.g., active ulcer within 6 months);
  6. Individual or family history of medullary thyroid cancer (MTC), type 2 multiple endocrine neoplasia syndrome or other hereditary diseases predisposing to MTC; abnormal and clinically significant thyroid function at screening, requiring pharmacological treatment or not yet clinically stable after treatment;
  7. Subjects with history of or current cholestasis or gallbladder stones (previous gallstone removal or lithotripsy) and/or cholecystectomy, who have no further sequelae, can enter into the study at the discretion of the investigator after assessing the risk;
  8. History of chronic malabsorption syndrome;
  9. Subjects with hematological diseases (e.g., aplastic anemia, myelodysplastic syndrome) or any disease causing hemolysis or erythrocyte instability (e.g., malaria);
  10. Severe systemic infectious diseases within 1 month prior to screening;
  11. Systolic blood pressure ≥160 mmHg and/or diastolic blood pressure ≥100 mmHg during screening;
  12. Any of the following serious cardiovascular and cerebrovascular events prior to screening: unstable angina pectoris requiring hospitalization, myocardial infarction, coronary artery bypass grafting, percutaneous coronary intervention (except for diagnostic angiography), moderate to severe congestive heart failure ( grade III or IV), atrial or ventricular arrhythmia requiring hospitalization (e.g., atrial fibrillation, ventricular tachycardia, tec.), second degree or third degree atrioventricular block without a pacemaker, clinically significant long syndrome or prolonged QTc interval, signs of localized ischemic heart disease, pacemaker or defibrillator implantation, stroke or or cerebrovascular accident within 6 months, or planned coronary artery bypass grafting or revascularization;
  13. The white blood cell count exceeds 10% of the normal range, or \<100 g/L during the screening period;
  14. (AST) or Alanine aminotransferase (ALT) ≥ 2.5 x (ULN), or fasting triglyceride ≥ 5.64 mmol/L or \< 60mL/(min*1.73 m2) during the screening period;
  15. History of severe respiratory tract, blood system, central nervous system diseases (e.g., epilepsy, etc.), or history of malignant tumor, mental diseases (e.g., depression, anxiety, etc.), or history of other diseases that may endanger the safety of the subjects and are considered unsuitable for this study in the investigator's opinion;
  16. Use of approved weight-lowering pharmacotherapy (e.g., orlistat) within 3 months prior to the first dose;
  17. History of surgical treatment for obesity (except for liposuction performed one year ago);
  18. Have used incretin analogues or other drugs that might interfere with the trial in the opinion of the investigator within 3 months before the first dose;
  19. History of drug abuse or dependence within 5 years prior to screening, with a positive urine drugs of abuse testing at screening;
  20. Average alcohol intake is more than 21 units of alcohol (male)/14 units of alcohol (female) per week within the 3 months prior to screening, or positive alcohol breath test before administration;
  21. Smoke more than 5 cigarettes per day within 3 months prior to screening;
  22. Blood lost ≥ 400 mL due to trauma or major surgery or blood donation ≥ 400 mL within 3 months prior to screening;
  23. Have participated in any clinical trial involving an product within 3 months prior to screening;
  24. Vaccinated within 28 days before screening or planned to be vaccinated within 1 week after receiving the study drug;
  25. Have a positive test result for surface antigen, antibody, anti- antibody or anti-Treponema pallidum specific antibody;
  26. Pregnant (blood pregnancy test positive at screening) and lactating female, or male and female planned to have children during the trial or within 6 months after the last dose;
  27. Not suitable for this study in the investigator's opinion.
Terms in these criteria, in plain language(17)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
48 participants (actual)

Study arms

  • Experimental
    TG103 injection 15 mg

    TG103 injection (15 mg, N=12) and Placebo (N=4) will be administered subcutaneously once weekly in overweight/obese non-diabetic subjects.

    Drug: TG103 injection · Drug: Placebo

  • Experimental
    TG103 injection 22.5 mg

    TG103 injection (22.5 mg, N=12) and Placebo (N=4) will be administered subcutaneously once weekly in overweight/obese non-diabetic subjects.

    Drug: TG103 injection · Drug: Placebo

  • Experimental
    TG103 injection 30 mg

    TG103 injection (30 mg, N=12) and Placebo (N=4) will be administered subcutaneously once weekly in overweight/obese non-diabetic subjects.

    Drug: TG103 injection · Drug: Placebo

Interventions

  • TG103 injection, SC, once weekly

  • DrugPlacebo

    Placebo control, SC, once weekly

06

What researchers measure

Primary outcomes

  1. Safety and tolerability assessed by incidence and severity of adverse events

    Time frame: Up to 99 days

Secondary outcomes

  1. PK profile-AUC: Area under the plasma concentration versus time curve

    Time frame: Day1, 8, 15, 22, 29, 64, 71, and 78

  2. PK profile- Cmax: Peak Plasma Concentration

    Time frame: Day1, 8, 15, 22, 29, 64, 71, and 78

  3. PK profile- Tmax: Time to maximum plasma concentration

    Time frame: Day1, 8, 15, 22, 29, 64, 71, and 78

  4. PK profile- t1/2: Half time

    Time frame: Day1, 8, 15, 22, 29, 64, 71, and 78

  5. PK profile- CL/F: Apparent clearance

    Time frame: Day1, 8, 15, 22, 29, 64, 71, and 78

  6. PD profile- Weight change relative to baseline

    Time frame: Day1, 8, 15, 22, 29, 36, 43, 50, 57, 64, 71, 78, 85 and 99

  7. PD profile- Proportion of subjects with a baseline weight loss of more than 5 percent

    Time frame: Day1, 8, 15, 22, 29, 36, 43, 50, 57, 64, 71, 78, 85 and 99

  8. PD profile- Waistline change relative to baseline

    Time frame: Day8, 15, 22, 29, 43, 57, 71, 78, 85 and 99

  9. PD profile- Change of waist-hip ratio relative to baseline

    Time frame: Day8, 15, 22, 29, 43, 57, 71, 78, 85 and 99

  10. PD profile- Change of blood pressure(systolic blood pressure and diastolic blood pressure)relative to baseline

    Time frame: Day15, 22, 29, 43, 85 and 99

  11. PD profile- Change of blood fat levels relative to baseline

    Time frame: Day15, 22, 29, 43, 85 and 99

  12. The occurrence of TG103 anti-drug antibodies (ADA)

    Time frame: Day1, 15, 29, 57, and 99

07

Study locations

1 site
  • Gao Huanhuan
    Beijing, 河北省 050035, China
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jul 2021 to primary completion in Dec 2022, 17 months.

Of 171 industry-sponsored phase 1 interventional studies under Diabetes Mellitus, half reached primary completion within 6 months of starting (the median), counting those still running; a quarter within 2 and three quarters within 10. This study's 17 months is above that.

Counting every sponsor, half of 247 studies reached it within 7 months; a quarter within 3 and three quarters within 17.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 19, 2021
First posted
Apr 22, 2021
StartActual
Jul 1, 2021
Primary completionActual
Dec 1, 2022
CompletionActual
Jan 1, 2023
Last update
Jun 22, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 22, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04855292
Responsible party
Sponsor
First posted
Apr 22, 2021
Start date
Jul 1, 2021
Primary completion
Dec 1, 2022
Completion
Jan 1, 2023
Last update
Jun 22, 2023

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: TG103

Start the discussion